$RLFTF Additional research... Mike Irwin @MikeIrw83705691 on twitter found this paper regarding the application of VIP and makes the point that VIP is found throughout the body (not just the lungs) and has therapeutic effects beyond the lungs:
"In this review, we describe the pathology of several major neurological disorders and discuss the potential pharmacotherapeutic role of VIP and its receptors for the treatment of disorders such as Alzheimer’s disease, Parkinson’s disease, and Autism Spectrum Disorders."
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC...231918.pdf
- Uncle Gee Gee DD (copy)
by jtb3 Q. saw this posted on the RLFTF FB group... i need to verify the source
"The treatment of cancer patients can no longer be imagined without innovative immunotherapies. However, they also repeatedly lead to life-threatening inflammation of the lungs.
Scientists and doctors at the Freiburg University Medical Center have now successfully used a novel therapeutic approach on a patient. The patient had received immunotherapy for melanoma, also known as black skin cancer.
However, this triggered severe pneumonia. The doctors decided to give him the intestinal hormone “vasoactive intestinal peptide” (VIP) for inhalation, the use of which is being researched at the Freiburg University Medical Center for similar diseases.
The pneumonia disappeared completely within a few weeks, something that had not previously been possible with cortisone.
The case report was published on Jan.New England Journal of Medicine published."
Vasoactive Intestinal Peptide treats Respiratory Failure in COVID-19 by rescuing the Alveolar Type II cell Jonathan C. Javitt, MD, MPH
"VIP binds uniquely to receptors on Alveolar Type II cells in the lung, the same cells that bind the SARS-CoV-2 virus via their ACE2 receptors. VIP protects those cells and the surrounding pulmonary epithelium by blocking cytokines, preventing apoptosis, and upregulating the production of surfactant, the loss of which is increasingly implicated in COVID-19 respiratory failure."
https://www.authorea.com/users/321659/article...7ee4b95e20
AT2 cells are slow to grow, even in healthy lungs.
"In the normal lung, type II cells proliferate to provide daughter cells, some of which remain as type II cells and some of which transdifferentiate to become type I cells. The turnover of alveolar epithelial cells in the normal lung is slow and estimated to be in the order of 2–3 weeks."
Biology of alveolar type II cells
Tangentially, AT2 cells have been difficult to grow in the lab (in vitro), so studying them was difficult in the past.
Successful Establishment of Primary Type II Alveolar Epithelium with 3D Organotypic Coculture
There is no medical/scientific claim, or indication (yet anyway) that Aviptadil "repairs" the Alveolar Type II cells. Importantly, though, it arrests the further degradation of them giving the body a fighting chance to begin to replenish them (over several weeks).
We are all wishing Captain Searcy well, but since he was placed on Aviptadil, basically, at the "last minute", expectations of drastically improved chest xrays in a matter of a few days are not realistic. Such a situation (on "death bed"
will probably turn out to be the exception, not the rule when it comes to Aviptadil. People in such dire conditions will most likely take week(s) to recover significant amounts of their AT2 cells. At least, that's what the outcomes look like with the data available at this time.
The fact that his chest xrays have not gotten worse is a good sign. It appears that the assault on his Alveolar Type II cells from Covid has been at least stopped.
He appears to be a fighter...a fighter who still has a ways to go.
Quote:
I know we are all wishing the best for him. Please understand that he was really bad off before RLF-100. Before RLF-100 was on the scene, he was on ECMO and was given 1 to 2 days to live.
- inelgr
"In this review, we describe the pathology of several major neurological disorders and discuss the potential pharmacotherapeutic role of VIP and its receptors for the treatment of disorders such as Alzheimer’s disease, Parkinson’s disease, and Autism Spectrum Disorders."
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC...231918.pdf
- Uncle Gee Gee DD (copy)
by jtb3 Q. saw this posted on the RLFTF FB group... i need to verify the source
"The treatment of cancer patients can no longer be imagined without innovative immunotherapies. However, they also repeatedly lead to life-threatening inflammation of the lungs.
Scientists and doctors at the Freiburg University Medical Center have now successfully used a novel therapeutic approach on a patient. The patient had received immunotherapy for melanoma, also known as black skin cancer.
However, this triggered severe pneumonia. The doctors decided to give him the intestinal hormone “vasoactive intestinal peptide” (VIP) for inhalation, the use of which is being researched at the Freiburg University Medical Center for similar diseases.
The pneumonia disappeared completely within a few weeks, something that had not previously been possible with cortisone.
The case report was published on Jan.New England Journal of Medicine published."
Vasoactive Intestinal Peptide treats Respiratory Failure in COVID-19 by rescuing the Alveolar Type II cell Jonathan C. Javitt, MD, MPH
"VIP binds uniquely to receptors on Alveolar Type II cells in the lung, the same cells that bind the SARS-CoV-2 virus via their ACE2 receptors. VIP protects those cells and the surrounding pulmonary epithelium by blocking cytokines, preventing apoptosis, and upregulating the production of surfactant, the loss of which is increasingly implicated in COVID-19 respiratory failure."
https://www.authorea.com/users/321659/article...7ee4b95e20
AT2 cells are slow to grow, even in healthy lungs.
"In the normal lung, type II cells proliferate to provide daughter cells, some of which remain as type II cells and some of which transdifferentiate to become type I cells. The turnover of alveolar epithelial cells in the normal lung is slow and estimated to be in the order of 2–3 weeks."
Biology of alveolar type II cells
Tangentially, AT2 cells have been difficult to grow in the lab (in vitro), so studying them was difficult in the past.
Successful Establishment of Primary Type II Alveolar Epithelium with 3D Organotypic Coculture
There is no medical/scientific claim, or indication (yet anyway) that Aviptadil "repairs" the Alveolar Type II cells. Importantly, though, it arrests the further degradation of them giving the body a fighting chance to begin to replenish them (over several weeks).
We are all wishing Captain Searcy well, but since he was placed on Aviptadil, basically, at the "last minute", expectations of drastically improved chest xrays in a matter of a few days are not realistic. Such a situation (on "death bed"
will probably turn out to be the exception, not the rule when it comes to Aviptadil. People in such dire conditions will most likely take week(s) to recover significant amounts of their AT2 cells. At least, that's what the outcomes look like with the data available at this time. The fact that his chest xrays have not gotten worse is a good sign. It appears that the assault on his Alveolar Type II cells from Covid has been at least stopped.
He appears to be a fighter...a fighter who still has a ways to go.
Quote:
I know we are all wishing the best for him. Please understand that he was really bad off before RLF-100. Before RLF-100 was on the scene, he was on ECMO and was given 1 to 2 days to live.
- inelgr
Mondobiotech Holding AG Basel (RLFTF) Stock Research Links
$MJ
